Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARWR 
Arrowhead Pharmaceuticals Inc (ARWR)
Today’s top pick
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: ARWR (4-star) is a STRONG-BUY. BUY since 6 days. Simulated Profits (39.09%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $57.67
1 Year Target Price $57.67
| 7 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 42.56% | Avg. Invested days 24 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.01B USD | Price to earnings Ratio - | 1Y Target Price 57.67 |
Price to earnings Ratio - | 1Y Target Price 57.67 | ||
Volume (30-day avg) 15 | Beta 1.31 | 52 Weeks Range 9.57 - 66.23 | Updated Date 12/2/2025 |
52 Weeks Range 9.57 - 66.23 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Earnings Date
Report Date 2025-12-01 | When - | Estimate -0.3099 | Actual -0.18 |
Profitability
Profit Margin -0.2% | Operating Margin (TTM) 17.2% |
Management Effectiveness
Return on Assets (TTM) 4.87% | Return on Equity (TTM) 8.67% |
Valuation
Trailing PE - | Forward PE 111.11 | Enterprise Value 7086205637 | Price to Sales(TTM) 9.66 |
Enterprise Value 7086205637 | Price to Sales(TTM) 9.66 | ||
Enterprise Value to Revenue 8.54 | Enterprise Value to EBITDA 42.99 | Shares Outstanding 135809558 | Shares Floating 116785355 |
Shares Outstanding 135809558 | Shares Floating 116785355 | ||
Percent Insiders 4.49 | Percent Institutions 84.5 |
Upturn AI SWOT
Arrowhead Pharmaceuticals Inc
Company Overview
History and Background
Arrowhead Pharmaceuticals, Inc. was founded in 1989 and initially focused on gene therapy. Over time, it shifted its focus to RNA interference (RNAi) therapeutics. A significant milestone was the development of the Targeted RNAi Molecule (TRiM) platform. They have evolved into a leader in RNAi-based drug development.
Core Business Areas
- RNAi Therapeutics Development: Arrowhead's core business involves developing RNAi-based therapeutics for various diseases. Their TRiM platform enables targeted delivery of RNAi molecules to specific tissues and cells.
Leadership and Structure
Arrowhead is led by its President and CEO. The company has a structured organizational framework encompassing research, development, clinical trials, and business development divisions.
Top Products and Market Share
Key Offerings
- ARO-AAT: ARO-AAT is being developed for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATD). It is in Phase 2/3 clinical trials. There is no direct market share data yet as the drug is not approved. Competitors include Vertex Pharmaceuticals (VRTX) and Alnylam Pharmaceuticals (ALNY), which are also developing AATD therapies.
- ARO-APOC3: ARO-APOC3 is being developed for the treatment of hypertriglyceridemia. It is in Phase 3 trials. There is no direct market share data yet as the drug is not approved. Competitors include Amgen (AMGN) with their approved drug for hypertriglyceridemia.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investments in R&D. RNAi therapeutics are a growing segment, offering a novel approach to drug development.
Positioning
Arrowhead is a leader in RNAi therapeutics, possessing a strong TRiM platform and a pipeline of promising drug candidates. Their competitive advantage lies in targeted drug delivery.
Total Addressable Market (TAM)
The TAM for RNAi therapeutics is estimated to be in the billions of dollars, growing as new therapies are developed for various diseases. Arrowhead is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Proprietary TRiM platform
- Strong pipeline of RNAi therapeutics
- Experienced management team
- Focus on targeted drug delivery
Weaknesses
- Dependence on successful clinical trial outcomes
- High R&D costs
- Limited commercialized products
- Competition from established pharmaceutical companies
Opportunities
- Expansion of the RNAi platform to new disease targets
- Partnerships and collaborations with larger pharmaceutical companies
- Potential for breakthrough therapies in underserved markets
- Advancements in drug delivery technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from alternative therapies
- Patent disputes
Competitors and Market Share
Key Competitors
- ALNY
- MRNA
- VRTX
Competitive Landscape
Arrowhead possesses a strong RNAi platform and a targeted drug delivery system; however they remain a smaller player overall. Arrowhead is an up and coming player.
Growth Trajectory and Initiatives
Historical Growth: Arrowhead's growth has been driven by the advancement of its RNAi platform and the progress of its clinical pipeline. There have been strong spikes in revenue and declines over the past several years.
Future Projections: Analyst estimates suggest continued growth as Arrowhead's clinical programs advance and potentially commercialize. They are expected to be one of the leaders in the market.
Recent Initiatives: Recent initiatives include focusing on strategic collaborations and partnerships with larger pharmaceutical companies.
Summary
Arrowhead Pharmaceuticals is a biotechnology company specializing in RNAi therapeutics. The company's proprietary TRiM platform enables targeted drug delivery, offering a competitive edge. The company faces challenges such as clinical trial risk and competition, it is a pioneer in its industry. Arrowhead needs to carefully manage their R&D costs and ensure successful clinical outcomes to capitalize on opportunities in the growing RNAi market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Company Website
- Various financial data providers
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arrowhead Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 1993-06-16 | Chairman, CEO & President Dr. Christopher R. Anzalone Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 711 | Website https://arrowheadpharma.com |
Full time employees 711 | Website https://arrowheadpharma.com | ||
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Pasadena, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.